Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis
Aim. Using the prospective Registry data, to assess the effects of conventional and specific therapy on the clinical course and survival of the patients with pulmonary arterial hypertension (PAH). Material and methods. The study included 124 patients (mean age 38,2±13,7 years; 34 men and 78 women):...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2012-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1878 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250246588104704 |
|---|---|
| author | N. S. Goncharova A. V. Kazymly A. V. Naimushin O. M. Moiseeva |
| author_facet | N. S. Goncharova A. V. Kazymly A. V. Naimushin O. M. Moiseeva |
| author_sort | N. S. Goncharova |
| collection | DOAJ |
| description | Aim. Using the prospective Registry data, to assess the effects of conventional and specific therapy on the clinical course and survival of the patients with pulmonary arterial hypertension (PAH). Material and methods. The study included 124 patients (mean age 38,2±13,7 years; 34 men and 78 women): 31 with idiopathic PAH (IPAH), 52 with Eisenmenger syndrome, 17 with inoperable chronic thromboembolic pulmonary hypertension, 9 with PAH and corrected congenital heart disease, 6 with PAH and systemic scleroderma, and 6 with PAH and HIV infection. Results. The cumulative one-year and three-year survival rates were 94% and 75%, respectively. Irrespective of the absence of right heart catheterisation and vasoreactive testing, 42,7% of the patients were treated with calcium antagonists. PAH-specific therapy was administered to 40,3% of the participants (64,5% and 21% of those with IPAH and Eisenmenger syndrome, respectively). PAH-specific therapy was associated with an increase in survival time. Conclusion. In PAH patients, the prognosis is linked to early administration of specific monotherapy and possible combination therapy. Developing a national registry of pulmonary hypertension will facilitate the assessment of the real-world demand for specific therapy and the related costs. |
| format | Article |
| id | doaj-art-cf37a91830b34f96a90f18aa0fec8d3e |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2012-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-cf37a91830b34f96a90f18aa0fec8d3e2025-08-20T03:57:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252012-08-01114798410.15829/1728-8800-2012-4-79-841593Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysisN. S. Goncharova0A. V. Kazymly1A. V. Naimushin2O. M. Moiseeva3V. A. Almazov Federal Centre of Heart, Blood, and Endocrinology, St. PetersburgV. A. Almazov Federal Centre of Heart, Blood, and Endocrinology, St. PetersburgV. A. Almazov Federal Centre of Heart, Blood, and Endocrinology, St. PetersburgV. A. Almazov Federal Centre of Heart, Blood, and Endocrinology, St. PetersburgAim. Using the prospective Registry data, to assess the effects of conventional and specific therapy on the clinical course and survival of the patients with pulmonary arterial hypertension (PAH). Material and methods. The study included 124 patients (mean age 38,2±13,7 years; 34 men and 78 women): 31 with idiopathic PAH (IPAH), 52 with Eisenmenger syndrome, 17 with inoperable chronic thromboembolic pulmonary hypertension, 9 with PAH and corrected congenital heart disease, 6 with PAH and systemic scleroderma, and 6 with PAH and HIV infection. Results. The cumulative one-year and three-year survival rates were 94% and 75%, respectively. Irrespective of the absence of right heart catheterisation and vasoreactive testing, 42,7% of the patients were treated with calcium antagonists. PAH-specific therapy was administered to 40,3% of the participants (64,5% and 21% of those with IPAH and Eisenmenger syndrome, respectively). PAH-specific therapy was associated with an increase in survival time. Conclusion. In PAH patients, the prognosis is linked to early administration of specific monotherapy and possible combination therapy. Developing a national registry of pulmonary hypertension will facilitate the assessment of the real-world demand for specific therapy and the related costs.https://cardiovascular.elpub.ru/jour/article/view/1878pulmonary arterial hypertensionspecific therapyconventional therapy |
| spellingShingle | N. S. Goncharova A. V. Kazymly A. V. Naimushin O. M. Moiseeva Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis Кардиоваскулярная терапия и профилактика pulmonary arterial hypertension specific therapy conventional therapy |
| title | Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis |
| title_full | Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis |
| title_fullStr | Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis |
| title_full_unstemmed | Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis |
| title_short | Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis |
| title_sort | contemporary treatment of pulmonary arterial hypertension the north west registry data analysis |
| topic | pulmonary arterial hypertension specific therapy conventional therapy |
| url | https://cardiovascular.elpub.ru/jour/article/view/1878 |
| work_keys_str_mv | AT nsgoncharova contemporarytreatmentofpulmonaryarterialhypertensionthenorthwestregistrydataanalysis AT avkazymly contemporarytreatmentofpulmonaryarterialhypertensionthenorthwestregistrydataanalysis AT avnaimushin contemporarytreatmentofpulmonaryarterialhypertensionthenorthwestregistrydataanalysis AT ommoiseeva contemporarytreatmentofpulmonaryarterialhypertensionthenorthwestregistrydataanalysis |